Contemporary trends on expenditure of hospital care on total cancer and its subtypes in China during

来源 :中国癌症研究(英文版) | 被引量 : 0次 | 上传用户:huaduo4851
下载到本地 , 更方便阅读
声明 : 本文档内容版权归属内容提供方 , 如果您对本文有版权争议 , 可与客服联系进行内容授权或下架
论文部分内容阅读
Objective:To describe the contemporary trends in total,inpatient,and outpatient expenditure on major subtypes of cancer in different classifications of hospitals in mainland China.Methods:Home page of Inpatient Medical Records (HIMRs) and Hospital Annual Reports (HARs) were used to estimate hospital care expenditure on cancer.Inpatient payments and their share of cancer were calculated with the top-down method.Kriging spatial interpolation methods were used at the county level and summed at the province level.Outpatient expenditure was estimated with inpatient expenditure and the ratios of outpatient to inpatient payments in specialized cancer hospitals,stratified by province.Total expenditure on cancer was the sum of both payments.Log-linear regression was applied to estimate annual percentage change (APC) of expenditure.Results:Total expenses for cancer of Chinese residents reached up to 304.84 billion Chinese Yuan (CNY) in 2017,accounting for 5.8% of the total health expenses (THE).After adjusting for consumer price index (CPI),medical expenses for cancer have increased from 63.30 billion CNY in 2008 to 249.56 billion CNY in 2017[APC:15.2%,95% confidence interval (95% CI):13.4%-17.0%].The APC was shghtly higher than THE around 2013,while was lower after 2013.During 2008-2017,the ratio of inpatient to outpatient costs for cancer decreased from 4.3:1 to 3.8:1.The inpatient payments for cancer mainly happened in grade 3 general hospitals,East China,and among lung,colorectal,and stomach cancer;while the fastest increase was found in West China,and among thyroid,prostate,and colorectal cancer.Conclusions:During 2008-2017,the rapid growth trend of medical expenses for cancer has been effectively controlled with the continuous deepening of medical reform and improvements of residents\' health care.More attention should be paid to potential increases of medical costs caused by technological progress and demand release.Socialized and multi-channel insurance financing modes should be explored in the future.
其他文献
多系统萎缩( Multiple system atrophy,MSA)是一种成人发病的逐渐进展的神经退行性疾病,临床表现是包括自主神经功能障碍、对左旋多巴类药物治疗反应欠佳的帕金森综合征和小脑性共济失调等症状.病理特点是:少突胶质细胞内有α-突触核蛋白阳性的包涵体( glial cytoplasmic inclusions, GCI) [1].中枢自主神经网络系统受损而节后去甲肾上腺素能神经元保存相对完整[2] ,是MSA与其他帕金森综合征的鉴别点[3].心血管系统损伤是导致MSA致残率高的原因之一,极大
目的 探讨癫痫合并颈肌阵挛的临床和神经电生理特点.方法 以“癫痫”和“颈肌阵挛”为关键词,在西京医院神经内科脑电监测中心数据库进行检索,检索时间为2018年1月至2020年1月.分析检索到的癫痫合并颈肌阵挛患者的临床和神经电生理特点,并随访.结果 4例符合癫痫合并颈肌阵挛的患者均为男性,均为遗传性全面性癫痫.3例为单纯强直阵挛发作癫痫,1例为眼睑肌阵挛伴失神癫痫,首次癫痫发作年龄9~27岁.2例患者在确诊癫痫及使用丙戊酸钠后出现颈肌阵挛,其中1例患者停用丙戊酸钠后颈肌阵挛消失.24 h V-EEG监测期间
迷走神经( vagus nerve,VN)是第10对脑神经,并且是脑神经中行程最长,分布范围最广的神经,含有四种纤维成分,属于副交感神经系统,与交感系统拮抗性地调整肝、肾等重要器官的功能以及心率,呼吸,腺体分泌等人体重要生理活动.人体通过迷走神经可以激活并整合复杂的神经、免疫、内分泌调节网络,调节人类炎症,疼痛及神经和精神心理相关疾病[1].迷走神经刺激术(vagus nerve stimulation,VNS),是通过外科手术的方式将相关装置在局部或全身麻醉的情况下,植入左颈部迷走神经周围或左锁骨下方的
重症肌无力( myasthenia gravis,MG)是一种由自身抗体介导的破坏神经肌肉接头( neuromuscular junction,NMJ)信号传递的自身免疫性疾病,以骨骼肌无力和易疲劳为主要临床表现[1,2].研究发现抗 AchR-Ab、MUSK-Ab 等其他针对胞内、胞外抗原的抗体通过一系列不同的机制,参与了MG致病的过程.血清抗体对MG的临床诊断、治疗、管理及预后的评估都具有重要意义,本文对MG相关抗体的形态结构、致病机制、临床意义相关进展综述如下.
颈部静脉属于较为关键且暴露的回流部位,其向上与颅内静脉回流相承接,向下回流至上腔静脉及右心房.而多普勒超声是评价血管系统最常用的成像技术,具有可视化、无创、简便、快捷、安全的特征.颈静脉的超声检测技术凭借其技术优势,可对平卧位状态下的患者进行颈部静脉的结构位置、回流状态、静脉瓣活动、血栓形成与否等进行评估.这一技术为临床工作带来极大的价值,可对患者的颈内静脉( In-ternal jugular vein,IJV)及颅内静脉是否存在狭窄进行评估,进行中心静脉置管指导,有无血栓形成及对颈静脉球瘤的判断等.
Lung cancer is the leading cause of cancer-related mortality globally,accounting for 1.8 million deaths in 2020.While the vast majority are caused by tobacco smoking,15%-25% of all lung cancer cases occur in lifelong never-smokers.The International Agency
In the last decade,the focus of computational pathology research community has shifted from replicating the pathological examination for diagnosis done by pathologists to unlocking and discovering “sub-visual” prognostic image cues from the histopathologi
Curative therapy was not previously available for patients with advanced non-small cell lung cancer (NSCLC);thus,the concept of minimal/measurable (or molecular) residual disease (MRD) was not applicable to these patients.However,advances in targeted and
Objective:To develop and validate a radiomics prognostic scoring system (RPSS) for prediction of progression-free survival (PFS) in patients with stage Ⅳ non-small cell lung cancer (NSCLC) treated with platinum-based chemotherapy.Methods:In this retrospec
Objective:Benefits of adjuvant treatment in pT1N1 gastric cancer (GC) remain controversial.Additionally,an effective biomarker for early GC is the need of the hour.The prognostic and predictive roles of single patient classifier (SPC) were validated in st